TherapeuticsMD, Inc.

TXMD Nasdaq SEC CIK 25743
Follow TherapeuticsMD Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $869K −8.7% vs same quarter last year
Net income $155K −71.9% vs same quarter last year
EPS, diluted $0.01 −80% vs same quarter last year
Operating cash flow $779K +104.5% vs same quarter last year
Revenue by quarter
$547K
$667K
$393K
$952K
$784K
$893K
$724K
$869K
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
  • Revenue
  • Net income
−$200M−$100M$0$100M$200MFY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$3M−$569K
FY24$1.8M−$2.2M
FY23$1.3M−$10.3M
FY22$70M$112M
FY21$2.6M−$172.4M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%2000%FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY25-−145.3%−18.8%
FY24-−347.1%−123.9%
FY23100%−654.6%−789.4%
FY2298%1.7%160.1%
FY2145.5%−3092.8%−6700.9%
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • TherapeuticsMD
  • Healthcare median
−8000%−6000%−4000%−2000%0%2000%FY21FY22FY23FY24FY25
Show the numbers
YearTherapeuticsMDHealthcare median
FY25−18.8%9.8%
FY24−123.9%10.5%
FY23−789.4%5.3%
FY22160.1%12.7%
FY21−6700.9%10.8%

News

No stories filed under TherapeuticsMD yet - coverage appears here as the news feed clusters it.